Bath Savings Trust Co Sells 5,120 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bath Savings Trust Co lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 5.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,910 shares of the medical research company’s stock after selling 5,120 shares during the quarter. Bath Savings Trust Co’s holdings in Edwards Lifesciences were worth $9,142,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC grew its holdings in shares of Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $658,390,000. Alliancebernstein L.P. grew its holdings in shares of Edwards Lifesciences by 27.5% in the 4th quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock worth $1,632,040,000 after purchasing an additional 4,712,819 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of Edwards Lifesciences by 161.5% in the 4th quarter. Two Sigma Advisers LP now owns 3,503,803 shares of the medical research company’s stock worth $261,419,000 after purchasing an additional 2,164,100 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of Edwards Lifesciences by 655.9% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock worth $173,502,000 after purchasing an additional 2,017,801 shares during the last quarter. Institutional investors own 79.25% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on EW. Morgan Stanley reissued an “overweight” rating and set a $102.00 price objective on shares of Edwards Lifesciences in a report on Friday, July 14th. Royal Bank of Canada restated an “outperform” rating and set a $96.00 target price on shares of Edwards Lifesciences in a research report on Thursday, August 17th. Truist Financial upped their target price on shares of Edwards Lifesciences from $101.00 to $105.00 in a research report on Wednesday, July 19th. Robert W. Baird assumed coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 18th. They set an “outperform” rating and a $107.00 target price on the stock. Finally, TheStreet downgraded shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $92.42.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.24 during midday trading on Monday, reaching $72.96. 2,691,563 shares of the stock were exchanged, compared to its average volume of 3,162,895. Edwards Lifesciences Co. has a twelve month low of $67.13 and a twelve month high of $94.87. The company has a quick ratio of 2.30, a current ratio of 3.15 and a debt-to-equity ratio of 0.09. The company has a market cap of $44.35 billion, a P/E ratio of 32.01, a PEG ratio of 4.00 and a beta of 1.03. The stock’s 50 day simple moving average is $81.38 and its 200 day simple moving average is $83.98.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.51 billion. Edwards Lifesciences had a return on equity of 25.43% and a net margin of 24.56%. The company’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 earnings per share. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 4,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $73.71, for a total value of $331,695.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at $2,911,766.13. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $93.27, for a total value of $676,673.85. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,795,260.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 4,500 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $73.71, for a total value of $331,695.00. Following the sale, the vice president now owns 39,503 shares in the company, valued at $2,911,766.13. The disclosure for this sale can be found here. Insiders sold a total of 174,359 shares of company stock valued at $14,301,522 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.